<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - MEFLOQUINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>MEFLOQUINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of malaria</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                (consult product literature).</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of malaria</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight 45 kg and above)</strong><br/>
                250 mg once weekly, dose to be started 2&#8211;3 weeks before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children (body-weight 5&#8211;15 kg)</strong><br/>
                62.5 mg once weekly, dose to be started 2&#8211;3 weeks before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children (body-weight 16&#8211;24 kg)</strong><br/>
                125 mg once weekly, dose to be started 2&#8211;3 weeks before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children (body-weight 25&#8211;44 kg)</strong><br/>
                187.5 mg once weekly, dose to be started 2&#8211;3 weeks before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 1&#8211;17 years (body-weight 45 kg and above)</strong><br/>
                250 mg once weekly, dose to be started 2&#8211;3 weeks before entering endemic area and continued for 4 weeks after leaving.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid (particularly in the first trimester) unless the potential benefit outweighs the risk; however, studies of mefloquine in pregnancy (including use in the first trimester) indicate that it can be considered for travel to chloroquine-resistant areas.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Elimination may be prolonged; avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Manufacturer advises caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Avoid for prophylaxis if history of psychiatric disorders (including depression) or convulsions</li>
            <li>avoid for standby treatment if history of convulsions</li>
            <li>history of blackwater fever</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, diarrhoea, dizziness, headache, nausea, neuropsychiatric reactions, pruritus, visual disturbances, vomiting,
              </p>
              <p>
                <strong>veryRare:</strong> Optic neuropathy,
              </p>
              <p>
                <strong>notKnown:</strong> Alopecia, amnesia, anorexia, arrhythmias, arthralgia, ataxia, blood disorders, bradycardia, cataract, chest pain, confusion, drowsiness, dyspepsia, dyspnoea, encephalopathy, fever, flushing, hepatic failure, hyperhidrosis, hypertension, hypotension, leucocytosis, leucopenia, malaise, motor neuropathies, muscle weakness, myalgia, oedema, palpitation, panic attacks, pneumonitis, rash, seizures, sensory neuropathies, speech disturbances, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, tremor, vestibular disorders,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Tablet may be crushed and mixed with food such as jam or honey just before administration.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Inform travellers about adverse reactions of mefloquine and, if they occur, to seek medical advice on alternative antimalarials before the next dose is due. Also warn travellers about <b>importance</b> of avoiding mosquito bites, <b>importance</b> of taking prophylaxis regularly, and <b>importance</b> of immediate visit to doctor if ill within 1 year and especially within 3 months of return.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Cardiac conduction disorders
          </li>
          <li>
            epilepsy (avoid for prophylaxis)
          </li>
          <li>
              <strong>:</strong>
            not recommended in infants under 3 months (5 kg) in children
          </li>
          <li>
            traumatic brain injury
          </li>
        </ul>
        <ul>
          <li>
            <p>Mefloquine is associated with potentially serious neuropsychiatric reactions. Abnormal dreams, insomnia, anxiety, and depression occur commonly. Psychosis, suicidal ideation, and suicide have also been reported. Psychiatric symptoms such as nightmares, acute anxiety, depression, restlessness, or confusion should be regarded as potentially prodromal for a more serious event. If neuropsychiatric symptoms occur, patients should be advised to discontinue mefloquine and to seek immediate medical attention so that mefloquine can be replaced with an alternative antimalarial. Adverse reactions may occur and persist up to several months after discontinuation because mefloquine has a long half-life. Mefloquine is contraindicated for malaria prophylaxis in those with a history of psychiatric disorders or convulsions.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Manufacturer advises adequate contraception during prophylaxis and for 3 months after stopping (teratogenicity in <i>animal</i> studies).</p>
            </section>
      </section>


      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Mefloquine doses in BNF Publications may differ from those in product literature.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In children</h3>
              <p>Not licensed for use in children under 5 kg body-weight and under 3 months.</p>
            </section>
      </section>









      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contra-indicated in patients with hypersensitivity to quinine.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of MEFLOQUINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76524"><a href="../medicinalForm/PHP76524.html" data-target="#PHP76524" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
